Enrollment in this study is complete

PRESERVE: Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population

This study, initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), will evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. It will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.

PRESERVE is led by Co-Principal Investigators – Jonathan A. Coleman, MD, Urologist at Memorial Sloan Kettering Cancer Center and Arvin George, MD, Urologist at the University of Michigan.

Important Risk Information

AngioDynamics, the AngioDynamics logo, NanoKnife and the NanoKnife logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. © 2022 AngioDynamics, Inc. GL/ON/WP/1036 REV 02 02/2022. All other trademarks are property of their respective owners.

The NanoKnife System when used for the treatment of prostate cancer is an investigational device. Limited by United States law to investigational use.